Exclusive interviews with leading policymakers that convey the true policy message that impacts markets.
Reporting on key macro data at the time of release.
Real-time insight on key fixed income and fx markets.
- Emerging MarketsEmerging Markets
Real-time insight of emerging markets in CEMEA, Asia and LatAm region
- MNI ResearchMNI Research
Actionable insight on monetary policy, balance sheet and inflation with focus on global issuance. Analysis on key political risk impacting the global markets.
- About Us
Sign up now for free access to this content.
Please enter your details below and select your areas of interest.
Latest global polling from YouGov on trust in COVID-19 vaccines shows widespread trust in the two most prominent mRNA vaccines from Pfizer/BioNTech and Moderna, while Johnson & Johnson's single-dose vaccine, Russia's Sputnik-V, and the UK's Oxford/AstraZeneca vaccines all scored lower in the trust ratings. The lowest scoring vaccines of all were the Sinopharm and Sinovac vaccines developed in China, and Covaxin, developed in India.
- Full data tables: https://docs.cdn.yougov.com/junxv1uzcf/YouGov%20-%...
Chart 1. How safe, or unsafe, do you think the [X] vaccine is? Net safety shown.
Source: YouGov. 6-25 June 2021. N.b. Each dot represents one country's net safety rating.
- Trust in the Pfizer and Moderna vaccines is almost uniformly high across the board, with Bulgaria and France two outliers on the low side. However, both of these countries have high levels of vaccine hesitancy in general, with all other vaccines also receiving low trust scores from these nations.
- The UK is by some distance the most trusting of the AstraZeneca vaccine, perhaps not surprising given that it was the backbone of the country's rapid initial rollout. Trust in the US (where it is not approved) and many EU member states (where it has been either pulled from rollout or pulled from younger people) is also low.
- In a number of western states, vaccine uptake is beginning to plateau as those vulnerable to the coronavirus are increasingly double-vaccinated while younger people aged 18-30 are not coming forward in significant numbers to receive the vaccine.